Kineret (Anakinra)｜Rheumatoid Arthritis｜HongKong DengYue Medicine

Anakinra Application Scope

• Indications: Anakinra is indicated for the treatment of:

  • Moderately to severely active rheumatoid arthritis (RA) in adults who have failed one or more disease-modifying antirheumatic drugs (DMARDs).

  • Neonatal-Onset Multisystem Inflammatory Disease (NOMID), a form of Cryopyrin-Associated Periodic Syndromes (CAPS).

  • Deficiency of Interleukin-1 Receptor Antagonist (DIRA).

    

Anakinra Characteristics

• Ingredients: Anakinra is a recombinant, nonglycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra), produced using an E. coli bacterial expression system. ​

• Properties: Anakinra consists of 153 amino acids with a molecular weight of 17.3 kilodaltons. It differs from native human IL-1Ra by the addition of a single methionine residue at its amino terminus.

• Specification: Available as a 100 mg/0.67 mL solution in a single-use prefilled syringe for subcutaneous injection. The graduated syringe allows for doses between 20 mg and 100 mg. ​

• Packaging Specification: Supplied in cartons containing 7 prefilled syringes.

• Storage: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. ​

• Expiry Date: Refer to the expiration date printed on the packaging.​

• Executive Standard: Complies with FDA-approved standards for prescription medications.​

• Approval Number: FDA NDA #103950 (approved November 14, 2001).

• Date of Revision: Refer to the latest revision date on the prescribing information.​

• Manufacturer: Swedish Orphan Biovitrum AB.

Guidelines for the Use of Anakinra

• Dosage and Administration:

  • Rheumatoid Arthritis: 100 mg administered daily by subcutaneous injection at approximately the same time each day.

  • Severe Renal Insufficiency or End-Stage Renal Disease: Consider 100 mg every other day.

• Adverse Reactions:

  • Common adverse reactions include:

    • Injection-site reactions (71%)

    • Headache (12%)

    • Nausea (7%)

    • Diarrhea (7%)

    • Vomiting (14%)

    • Arthralgia (11.6%)

    • Pyrexia (11.6%)

    • Nasopharyngitis (11.6%)

• Contraindications: Known hypersensitivity to E. coli-derived proteins, Anakinra, or any components of the product.

• Precautions:

  • Monitor for signs of infection; Anakinra may increase the risk of serious infections.

  • Use with caution in patients with neutropenia; monitor neutrophil counts.

  • Avoid live vaccines during treatment. ​

Anakinra Interactions

• Drug Interactions:

  • Avoid concurrent use with Tumor Necrosis Factor (TNF) blocking agents due to increased risk of serious infections.

  • Live vaccines should be avoided during treatment and for at least 3 months after cessation. ​

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.